Dogs with Cognitive Dysfunction as a Spontaneous Model for Early Alzheimer's Disease: A Translational Study of Neuropathological and Inflammatory Markers

Journal of Alzheimer's Disease

Volumn 52, Issue 2, 2016, Pages 433-449

  Schütt, Trine ^a,b   Helboe, Lone ^b   Pedersen, Lars Østergaard ^b   Waldemar, Gunhild ^c   Berendt, Mette ^a   Pedersen, Jan Torleif ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b H LUNDBECK A S   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Aging; Alzheimer's disease; amyloid ; animal model; canine; dog; neurodegeneration

Indexed keywords

AMYLOID BETA PROTEIN; PYROGLUTAMIC ACID; TAU PROTEIN; CYTOKINE;

AGED; AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANINE COGNITIVE DYSFUNCTION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOG; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; IMMUNOREACTIVITY; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; SENILE PLAQUE; AMYLOID PLAQUE; ANIMAL; BRAIN; COMPARATIVE STUDY; DENMARK; DISEASE COURSE; DISEASE MODEL; DOG DISEASE; EPIDEMIOLOGY; FEMALE; IMMUNOLOGY; LONGITUDINAL STUDY; MALE; METABOLISM; PATHOLOGY; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SPECIES DIFFERENCE; TRANSLATIONAL RESEARCH;

AGING; ALZHEIMER DISEASE; ANIMALS; BRAIN; COGNITIVE DYSFUNCTION; CYTOKINES; DENMARK; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOG DISEASES; DOGS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LONGITUDINAL STUDIES; MALE; PLAQUE, AMYLOID; SEVERITY OF ILLNESS INDEX; SPECIES SPECIFICITY; TAU PROTEINS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84971281790     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-151085     Document Type: Article

References (87)

1. Adams B, Chan A, Callahan H, Milgram NW (2000) The canine as a model of human cognitive aging: Recent developments. Prog Neuro-Psychopharmacol Biol Psychiatry 24, 675-692.
2. Cummings BJ, Head E, Ruehl W, Milgram NW, Cotman CW (1996) The canine as an animal model of human aging and dementia. Neurobiol Aging 17, 259-268.
3. Landsberg GM, Nichol J, Araujo JA (2012) Cognitive dysfunction syndrome: A disease of canine and feline brain aging. Vet Clin North Am Small Anim Pract 42, 749-768.
4. Schutt T, Toft N, BerendtM(2015) Cognitive function, progression of age-related behavioral changes, biomarkers, and survival in dogs more than 8 years old. J Vet Intern Med 29, 1569-1577.
5. Davis PR, Head E (2014) Prevention approaches in a preclinical canine model of Alzheimer's disease: Benefits and challenges. Front Pharmacol 5, Article 47.
6. Studzinski CM, Araujo JA, MilgramNW(2005) The canine model of human cognitive aging and dementia: Pharmacological validity of the model for assessment of human cognitive-enhancing drugs. Prog Neuro-Psychopharmacol Biol Psychiatry 29, 489-498.
7. RuehlWW, Bruyette DS, DePaoli A, Cotman CW, Head E, Milgram NW, Cummings BJ (1995) Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: Clinical presentation, cognitive testing, pathology and response to 1-deprenyl therapy. Prog Brain Res 106, 217-225.
8. Cotman CW, Head E (2008) The canine (dog) model of human aging and disease: Dietary, environmental and immunotherapy approaches. J Alzheimers Dis 15, 685-707.
9. Fast R, Schutt T, Toft N, Moller A, Berendt M (2013) An observational study with long-term follow-up of canine cognitive dysfunction: Clinical characteristics, survival, and risk factors. J Vet Intern Med 27, 822-829.
10. Pugliese M, Carrasco JL, Gomez-Anson B, Andrade C, Zamora A, Rodriguez MJ, Mascort J, Mahy N (2010) Magnetic resonance imaging of cerebral involutional changes in dogs as markers of aging: An innovative tool adapted from a human visual rating scale. Vet J 186, 166-171.
11. Rofina JE, Van Ederen AM, Toussaint MJM, Secreve M, Van DS,Van DM,Van Eerdenburg I, Gruys FJCM, E (2006) Cognitive disturbances in old dogs suffering from the canine counterpart of Alzheimer's disease. Brain Res 1069, 216-226.
12. Su MY, Tapp PD, Vu L, Chen YF, Chu Y, Muggenburg B, Chiou JY, Chen C, Wang J, Bracco C, Head E (2005) A longitudinal study of brain morphometrics using serial magnetic resonance imaging analysis in a canine model of aging. Prog Neuropsychopharmacol Biol Psychiatry 29, 389-397.
13. Tapp PD, Head K, Head E, Milgram NW, Muggenburg BA, Su MY (2006) Application of an automated voxel-based morphometry technique to assess regional gray and white matter brain atrophy in a canine model of aging. Neuroimage 29, 234-244.
14. Borras D, Ferrer I, PumarolaM(1999) Age-related changes in the brain of the dog. Vet Pathol 36, 202-211.
15. Cummings BJ, Head E, Afagh AJ, Milgram NW, Cotman CW(1996) beta-Amyloid accumulation correlates with cognitive dysfunction in the aged canine. Neurobiol Learn Mem 66, 11-23.
16. Head E, Pop V, Sarsoza F, Kayed R, Beckett TL, Studzinski CM, Tomic JL, Glabe CG, Murphy MP (2010) Amyloidbeta peptide and oligomers in the brain and cerebrospinal fluid of aged canines. J Alzheimers Dis 20, 637-646.
17. Satou T, Cummings BJ, Head E, Nielson KA, Hahn FF, Milgram NW, Velazquez P, Cribbs DH, Tenner AJ, Cotman CW (1997) The progression of beta-amyloid deposition in the frontal cortex of the aged canine. Brain Res 774, 35-43.
18. Czasch S, Paul S, Baumgartner W (2006) A comparison of immunohistochemical and silver staining methods for the detection of diffuse plaques in the aged canine brain. Neurobiol Aging 27, 293-305.
19. Colle M-, Hauw J-, Crespeau F, Uchihara T, Akiyama H, Checler F, Pageat P, Duykaerts C (2000) Vascular and parenchymal Abeta deposition in the aging dog: Correlation with behavior. Neurobiol Aging 21, 695-704.
20. Ishihara T, Gondo T, Takahashi M, Uchino F, Ikeda S-, Allsop D, Imai K (1991) Immunohistochemical and immunoelectron microscopical characterization of cerebrovascular and senile plaque amyloid in aged dogs' brains. Brain Res 548, 196-205.
21. Nakamura S, Tamaoka A, Sawamura N, Kiatipattanasakul W, Nakayama H, Shoji S,YoshikawaY, DoiK(1997) Deposition of amyloid beta protein (Abeta) subtypes Abeta40 and Abeta42(43)] in canine senile plaques and cerebral amyoloid angiopathy. Acta Neuropathol 94, 323-328.
22. Wegiel J,Wisniewski HM, Dziewiatkowski J, Tarnawski M, Nowakowski J, Dziewiatkowska A, Soltysiak Z (1995) The origin of amyloid in cerebral vessels of aged dogs. Brain Res 705, 225-234.
23. Siwak-Tapp CT, Head E, Muggenburg BA, Milgram NW, Cotman CW (2008) Region specific neuron loss in the aged canine hippocampus is reduced by enrichment. Neurobiol Aging 29, 39-50.
24. Siwak-Tapp CT, Head E, Muggenburg BA, Milgram NW, Cotman CW (2007) Neurogenesis decreases with age in the canine hippocampus and correlates with cognitive function. Neurobiol Learn Mem 88, 249-259.
25. Bernedo V, Insua D, Suarez ML, Santamarina G, Sarasa M, Pesini P (2009) Beta-amyloid cortical deposits are accompanied by the loss of serotonergic neurons in the dog. J Comp Neurol 513, 417-429.
26. Insua D, Suarez ML, Santamarina G, Sarasa M, Pesini P (2010) Dogs with canine counterpart of Alzheimer's disease lose noradrenergic neurons. Neurobiol Aging 31, 625-635.
27. Insua D, Corredoira A, Gonzalez-Martinez A, Suarez ML, Santamarina G, Sarasa M, Pesini P (2012) Expression of p75(NTR), a marker for basal forebrain cholinergic neurons, in young and aged dogs with or without cognitive dysfunction syndrome. J Alzheimers Dis 28, 291-296.
28. Araujo JA, Studzinski CM, Milgram NW (2005) Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging. Prog Neuro-Psychopharmacol Biol Psychiatry 29, 411-422.
29. Head E, Liu J, Hagen TM, Muggenburg BA, Milgram NW, Ames BN, Cotman CW (2002) Oxidative damage increases with age in a canine model of human brain aging. J Neurochem 82, 375-381.
30. Rofina JE, Singh K, Skoumalova-Vesela A,Van EderenAM, Van Asten AJAM, Wilhelm J, Gruys E (2004) Histochemical accumulation of oxidative damage products is associated with Alzheimer-like pathology in the canine. Amyloid 11, 90-100.
31. Skoumalova A, Rofina J, Schwippelova Z, Gruys E, Wilhelm J (2003) The role of free radicals in canine counterpart of senile dementia of the Alzheimer type. Exp Gerontol 38, 711-719.
32. Johnstone EM, Chaney MO, Norris FH, Pascual R, Little SP (1991) Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis. Mol Brain Res 10, 299-305.
33. Pop V, Head E, Berchtold NC, Glabe CG, Studzinski CM, Weidner AM, Murphy MP, Cotman CW (2012) Abeta aggregation profiles and shifts inAPPprocessing favor amyloidogenesis in canines. Neurobiol Aging 33, 108-120.
34. Sarasa L, Gallego C, Monleon I, Olvera A, Canudas J, Montanes M, Pesini P, SarasaM(2010) Cloning, sequencing and expression in the dog of the main amyloid precursor protein isoforms and some of the enzymes related with their processing. Neuroscience 171, 1091-1101.
35. Gallagher M, Rapp PR (1997) The use of animal models to study the effects of aging on cognition. Annu Rev Psychol 48, 339-370.
36. Braidy N, Munoz P, Palacios AG, Castellano-Gonzalez G, Inestrosa NC, Chung RS, Sachdev P, Guillemin GJ (2012) Recent rodent models for Alzheimer's disease: Clinical implications and basic research. J Neural Transm 119, 173-195.
37. Braidy N, Poljak A, Jayasena T, Mansour H, Inestrosa NC, Sachdev PS (2015) Accelerating Alzheimer's research through 'natural' animal models. Curr Opin Psychiatry 28, 155-164.
38. Sabbagh JJ, Kinney JW, Cummings JL (2013) Animal systems in the development of treatments for Alzheimer's disease: Challenges, methods, and implications. Neurobiol Aging 34, 169-183.
39. Gotz J, Ittner LM (2008) Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci 9, 532-544.
40. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403.
41. Bosch MN, Pugliese M, Gimeno-Bayon J, Rodriguez MJ, Mahy N (2012) Dogs with cognitive dysfunction syndrome: Anatural model of Alzheimer's disease. Curr Alzheimer Res 9, 298-314.
42. OpiiWO, Joshi G, Head E, MilgramNW, Muggenburg BA, Klein JB, Pierce WM, Cotman CW, Butterfield DA (2008) Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: Relevance to Alzheimer's disease. Neurobiol Aging 29, 51-70.
43. Salvin HE, McGreevy PD, Sachdev PS, Valenzuela MJ (2011) The canine cognitive dysfunction rating scale (CCDR): A data-driven and ecologically relevant assessment tool. Vet J 188, 331-336.
44. GarmanRH(2003) Evaluation of large-sized brains for neurotoxic endpoints. Toxicol Pathol 31 (Suppl.), 32-43.
45. Head E, McCleary R, Hahn FF, Milgram NW, Cotman CW (2000) Region-specific age at onset of beta-amyloid in dogs. Neurobiol Aging 21, 89-96.
46. Chambers JK, Mutsuga M, Uchida K, Nakayama H (2011) Characterization of AbetapN3 deposition in the brains of dogs of various ages and other animal species. Amyloid 18, 63-71.
47. Attems J, Jellinger K, Thal DR, Van NW (2011) Review: Sporadic cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 37, 75-93.
48. Head E, Callahan H, Muggenburg BA, Cotman CW, MilgramNW( 1998) Visual-discrimination learning ability and beta-amyloid accumulation in the dog. Neurobiol Aging 19, 415-425.
49. Kiatipattanasakul W, Nakamura SI, Hossain MM, Nakayama H, Uchino T, Shumiya S, Goto N, Doi K (1996) Apoptosis in the aged dog brain. Acta Neuropathol 92, 242-248.
50. Pugliese M, Geloso MC, Carrasco JL, Mascort J, Michetti F, Mahy N (2006) Canine cognitive deficit correlates with diffuse plaque maturation and S100beta (-) astrocytosis but not with insulin cerebrospinal fluid level. Acta Neuropathol 111, 519-528.
51. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM,HymanBT, IwatsuboT, Jellinger KA, Jicha GA,Kovari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM,Masliah E,McKeeAC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T,Woltjer RL, Beach TG (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol 71, 362-381.
52. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356.
53. Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, Morrison JH, Gold G, Hof PR (2003) Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60, 1495-1500.
54. Berg L, McKeel DW Jr, Miller JP, Storandt M, Rubin EH, Morris JC, Baty J, Coats M, Norton J, Goate AM, Price JL, Gearing M, Mirra SS, Saunders AM (1998) Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 55, 326-335.
55. Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791-1800.
56. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
57. Frost JL, Le KX, Cynis H, Ekpo E, Kleinschmidt M, Palmour RM, Ervin FR, Snigdha S, Cotman CW, Saido TC, Vassar RJ, George-Hyslop PS, Ikezu T, Schilling S, Demuth HU, Lemere CA (2013) Pyroglutamate-3 Amyloid-beta deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models. Am J Pathol 183, 369-381.
58. Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, Kalback WM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Roher AE (2001) Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem 276, 12991-12998.
59. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21, 372-381.
60. Cummings BJ, Satou T, Head E, Milgram NW, Cole GM, Savage MJ, Podlisny MB, Selkoe DJ, Siman R, Greenberg BD, CotmanCW(1996) Diffuse plaques contain C-terminal Abeta42 and not Abeta40: Evidence from cats and dogs. Neurobiol Aging 17, 653-659.
61. Cosentino SA, Stern Y, Sokolov E, Scarmeas N, Manly JJ, Tang MX, Schupf N, Mayeux RP (2010) Plasma ss-amyloid and cognitive decline. Arch Neurol 67, 1485-1490.
62. Song F, Poljak A, Valenzuela M, Mayeux R, Smythe GA, Sachdev PS (2011) Meta-analysis of plasma amyloidbeta levels in Alzheimer's disease. J Alzheimers Dis 26, 365-375.
63. Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O'Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC (2011) Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 69, 181-192.
64. Thal DR, Ghebremedhin E, Rub U, Yamaguchi H, Del TK, Braak H (2002) Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol 61, 282-293.
65. Tian J, Shi J, MannDM(2004) Cerebral amyloid angiopathy and dementia. Panminerva Med 46, 253-264.
66. Yoshino T, Uchida K, Tateyama S,Yamaguchi R, Nakayama H, Goto N (1996) A retrospective study of canine senile plaques and cerebral amyloid angiopathy. Vet Pathol 33, 230-234.
67. Attems J, Lintner F, Jellinger KA (2004) Amyloid beta peptide 1-42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology. Acta Neuropathol 107, 283-291.
68. Tian J, Shi J, Bailey K, Mann DM (2003) Negative association between amyloid plaques and cerebral amyloid angiopathy in Alzheimer's disease. Neurosci Lett 352, 137-140.
69. Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12, 723-738.
70. Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, Vitek MP, Hovanesian V, Stopa EG (2007) Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 28, 977-986.
71. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del TK (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112, 389-404.
72. Pugliese M, Mascort J, Mahy N, Ferrer I (2006) Diffuse beta-amyloid plaques and hyperphosphorylated tau are unrelated processes in aged dogs with behavioral deficits. Acta Neuropathol 112, 175-183.
73. Uchida K, Nakayama H, Tateyama S, Goto N (1992) Immunohistochemical analysis of constituents of senile plaques and cerebro-vascular amyloid in aged dogs. J Vet Med Sci 54, 1023-1029.
74. Yu C, Song G, Yhee J, Kim J, Im K, Nho W, Lee J, Sur J (2011) Histopathological and immunohistochemical comparison of the brain of human patients with Alzheimer's disease and the brain of aged dogs with cognitive dysfunction. J Comp Pathol 145, 45-58.
75. Wegiel J, Wisniewski HM, Soltysiak Z (1998) Regionand cell-type-specific pattern of tau phosphorylation in dog brain. Brain Res 802, 259-266.
76. Schmidt F, Boltze J, Jager C, Hofmann S,Willems N, Seeger J, Hartig W, Stolzing A (2015) Detection and quantification of beta-amyloid, pyroglutamyl Abeta, and tau in aged canines. J Neuropathol Exp Neurol 74, 912-923.
77. Smolek T, Madari A, Farbakova J, Kandrac O, Jadhav S, Cente M, Brezovakova V, Novak M, Zilka N (2016) Tau hyperphosphorylation in synaptosomes and neuroinflammation are associated with canine cognitive impairment. J Comp Neurol 524, 874-895.
78. Kuroki K, Uchida K, Kiattipattanasakul W, Nakamura S, Yamaguchi R, Nakayama H, Doi K, Tateyama S (1997) Immunohisotchemical detection of tau proteins in various non-human animal brains. Neuropathology 17, 174-180.
79. Nakayama H, Uchida K, Doi K (2004) A comparative study of age-related brain pathology-are neurodegenerative diseases present in nonhuman animals? Med Hypotheses 63, 198-202.
80. Martin SB, Dowling AL, Head E (2011) Therapeutic interventions targeting Beta amyloid pathogenesis in an aging dog model. Curr Neuropharmacol 9, 651-661.
81. Neus Bosch M, Pugliese M, Andrade C, Gimeno-Bayon J, Mahy N, Rodriguez MJ (2015) Amyloid-beta immunotherapy reduces amyloid plaques and astroglial reaction in aged domestic dogs. Neurodegener Dis 15, 24-37.
82. May PC,Willis BA, Lowe SL, Dean RA, Monk SA, Cocke PJ, Audia JE, Boggs LN, Borders AR, Brier RA, Calligaro DO, Day TA, Ereshefsky L, Erickson JA, Gevorkyan H, Gonzales CR, James DE, Jhee SS, Komjathy SF, Li L, Lindstrom TD, Mathes BM, Martenyi F, Sheehan SM, Stout SL, Timm DE, Vaught GM, Watson BM, Winneroski LL, Yang Z, Mergott DJ (2015) The potent BACE1 inhibitor LY2886721 elicits robust central Abeta pharmacodynamic responses in mice, dogs, and humans. J Neurosci 35, 1199-1210.
83. Qureshi AI, Suri MF, Ling GS, Khan J, Guterman LR, Hopkins LN (2001) Absence of early proinflammatory cytokine expression in experimental intracerebral hemorrhage. Neurosurgery 49, 416-420.
84. Zois NE, Moesgaard SG, Kjelgaard-Hansen M, Rasmussen CE, Falk T, Fossing C, Haggstrom J, Pedersen HD, Olsen LH (2012) Circulating cytokine concentrations in dogs with different degrees of myxomatous mitral valve disease. Vet J 192, 106-111.
85. Hickman SE, El Khoury J (2010) Mechanisms of mononuclear phagocyte recruitment in Alzheimer's disease. CNS Neurol Disord Drug Targets 9, 168-173.
86. Schwab C, McGeer PL (2008) Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J Alzheimers Dis 13, 359-369.
87. Schlachetzki JC, Hull M (2009) Microglial activation in Alzheimer's disease. Curr Alzheimer Res 6, 554-563.